SignatureFD’s Myriad Genetics MYGN Stock Holding History

SignatureFD’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.48K	Sell	609 -1,716	-74%	-$7.79K	﹤0.01%	2980
2026 Q1	$10.5K	Buy	2,325 +1,667	+253%	+$8.69K	﹤0.01%	2489
2025 Q4	$4.05K	Sell	658 -124	-16%	-$899	﹤0.01%	2765
2025 Q3	$5.65K	Sell	782 -11	-1%	-$65	﹤0.01%	2626
2025 Q2	$4.21K	Buy	+793	New	+$4.68K	﹤0.01%	2661
2024 Q4	–	Sell	-60	Closed	-$1.64K	–	3365
2024 Q3	$1.64K	Hold	60	–	–	﹤0.01%	2885
2024 Q2	$1.47K	Hold	60	–	–	﹤0.01%	2826
2024 Q1	$1.28K	Hold	60	–	–	﹤0.01%	2904
2023 Q4	$1.15K	Buy	+60	New	+$1.04K	﹤0.01%	2887
2023 Q2	–	Sell	-11	Closed	-$256	–	3323
2023 Q1	$256	Buy	+11	New	+$223	﹤0.01%	3165
2022 Q3	–	Sell	-104	Closed	-$2K	–	3258
2022 Q2	$2K	Buy	104 +11	+12%	+$228	﹤0.01%	2775
2022 Q1	$2K	Hold	93	–	–	﹤0.01%	2830
2021 Q4	$3K	Buy	+93	New	+$2.69K	﹤0.01%	2598
2019 Q4	–	Sell	-602	Closed	-$17K	–	2234
2019 Q3	$17K	Buy	+602	New	+$17.5K	﹤0.01%	1280
2018 Q3	–	Sell	-285	Closed	-$11K	–	1969
2018 Q2	$11K	Buy	+285	New	+$9.63K	﹤0.01%	1369

Other funds holding MYGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

SignatureFD's MYGN Position: Q2 2026 in Review

SignatureFD reduced its Myriad Genetics (MYGN) stake by 74% in Q2 2026, selling an estimated $7.79K and leaving 609 shares worth $3.48K. The position accounts for ﹤0.01% of the portfolio, ranked #2980.

SignatureFD first reported a position in MYGN in Q2 2018 and has held it in 15 quarters since. The position peaked at $17K in Q3 2019. 196 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

SignatureFD held 609 shares of Myriad Genetics worth $3.48K as of Q2 2026.
SignatureFD sold 1,716 Myriad Genetics shares in Q2 2026, an estimated $7.79K.
Myriad Genetics made up ﹤0.01% of SignatureFD's portfolio in Q2 2026, its #2980 holding.
SignatureFD first reported a position in Myriad Genetics in Q2 2018 and has held it in 15 quarters since.
SignatureFD's Myriad Genetics position peaked at $17K in Q3 2019.
196 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on SignatureFD's 13F filing for Q2 2026, filed 24 Jul 2026.